The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subgroup of breast tumors clinically defined by the lack of estrogen, progesterone and HER2 receptors, limiting the use of the targeted therapies employed in other breast malignancies. Recent evidence indicates that c-MYC is a k...

Descripción completa

Detalles Bibliográficos
Autores principales: Vázquez, Ramiro, Riveiro, María E, Astorgues-Xerri, Lucile, Odore, Elodie, Rezai, Keyvan, Erba, Eugenio, Panini, Nicolò, Rinaldi, Andrea, Kwee, Ivo, Beltrame, Luca, Bekradda, Mohamed, Cvitkovic, Esteban, Bertoni, Francesco, Frapolli, Roberta, D'Incalci, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352346/
https://www.ncbi.nlm.nih.gov/pubmed/27935867
http://dx.doi.org/10.18632/oncotarget.13814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352346/
https://www.ncbi.nlm.nih.gov/pubmed/27935867
http://dx.doi.org/10.18632/oncotarget.13814

Ejemplares similares